2
Jun
2026

Quotient Sceinces

Exhibitor at CPHI Americas 2026 stand 808
About Us

Quotient Sciences brings 35+ years of trusted scientific insight, quality, and control to drug development with a mission to help our customers bring new molecules to patients faster. We provide a full range of drug product (CDMO) and clinical (CRO) services, which can be tightly integrated with Translational Pharmaceutics®—a disruptive platform to enable greater efficiency, better outcomes, and reduced timelines in development.  

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2017
  • Employees:
    500 - 999
Company types
Academic/Research
Consultancy
Contract Service
Manufacturer/Innovator
Contact info
Event information
CPHI Americas 2026
  • 2 Jun 2026 - 4 June 2026
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 808

Products Featured at CPHI Americas 2026

  • Candidate Selection - Integrated Programs

    Product Candidate Selection - Integrated Programs

    Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment o...
  • Early Stage Development - Integrated Programs

    Product Early Stage Development - Integrated Programs

    Accelerating molecules through to proof-of-concept - Simplify early development and accelerate to Proof-of Concept.Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.With fully integrated capabil...
  • Late Stage Development - Integrated Programs

    Product Late Stage Development - Integrated Programs

    .Accelerating products through to commercial manufacture - Speed the journey from proof-of-concept to commercial launch. The journey from proof-of-concept to commercial launch can be complex. Speed is critical but it shouldn’t come at the expense of product quality. Creating patient-centric formulatio...
  • Drug Substance

    Product Drug Substance

    Our streamlined approach to developing drug substance has been shown to reduce manufacturing costs by 50% from preclinical to Phase I.  To best support our customer’s needs, we have made significant investments in technologies and equipment to meet the increasing demand for complex small-scale dr...
  • Formulation Development

    Product Formulation Development

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at a...

QUOTIENT SCIENCES LIMITED Resources (1)